The main objective of EBOVAC2 is to provide extensive and robust data on the safety and immunogenicity of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.

This will be done by:

1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates; 

2. Carrying out Phase 2 trials in African and European volunteers Given the compressed nature of this development program, the Phase 2 studies are anticipated to be conducted in parallel with the planned Phase 3 study (EBOVAC1). The Phase 2 studies will be controlled with either placebo or active control vaccinations with standard vaccines and will be conducted in locations where it is possible to perform carefully controlled safety studies;

3. Evaluating the use of the vaccine regimen in healthy population groups, such as children (aged 1-17 years), the elderly (ages 50-65) and individuals infected with HIV, to confirm safety and immunogenicity. It is intended that Phase 2 trials will begin as soon as preliminary safety data are available from Phase 1 trials;

4. Monitoring and characterising immune response to the proposed vaccine regimen;

5. Boosting the capacity of African centres and staff as well as communicating and disseminating the results of EBOVAC2 as they become available to all key stakeholders;

6. Contributing all data to the Central Information Repository (set up in EBOVAC1) for use by all Ebola+ programme projects as well as the wider community.

laboratory compressed                                                    © Janssen

News

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018

  • 02 January 2018

    The 4th edition of our EBOVAC2 newlsetter was released on the 21st of December 2017.

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research